Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC director Donald Zurbay reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, vested RSUs were settled into 2,560 ordinary shares under the company’s 2025 Director Incentive Award Plan. To cover tax obligations, 308 ordinary shares were withheld at $79.70 per share, leaving Zurbay with 2,252 ordinary shares directly held after the transactions. He also received a new grant of 2,383 RSUs that each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC reported a Form 144 notice showing a reported sale of 1,800 shares of Common Stock by Francesco Bianchi on 05/26/2026 for $136,350. The filing also lists restricted stock unit vesting events of 708 shares on 06/15/2024 and 492 shares on 06/29/2021, both noted as granted under the issuer's equity compensation plan. The excerpt includes a Common Stock figure of 54,933,538 with date 06/15/2026.
LivaNova PLC director Jette Nygaard-Andersen filed an initial Form 3 reporting her ownership in the company’s common stock. The filing shows she beneficially owns 0 shares of Common Stock directly following this reporting, and it does not report any purchase or sale transactions.
LivaNova PLC reported the results of its 2026 Annual General Meeting, where shareholders approved all 10 proposals presented. Eleven directors were re-elected for terms running until the 2027 AGM, maintaining continuity on the board.
Shareholders gave advisory approval to the U.S. say-on-pay vote for named executive officers and to the UK directors’ remuneration report. They also ratified PricewaterhouseCoopers LLP as both the U.S. independent registered public accounting firm and the UK statutory auditor for 2026 and authorized the board or Audit and Compliance Committee to set the UK auditor’s fees.
Investors renewed authority for directors to allot shares up to a nominal £10,985,296 and to disapply pre-emption rights on the same nominal amount. They also approved share repurchase contracts allowing buybacks of up to 10% of total issued ordinary shares as of April 13, 2026.
LivaNova PLC director Francesco Bianchi sold shares of the company. On May 26, 2026, he executed an open-market sale of 1,800 Ordinary Shares at an average price of $75.75 per share. After this transaction, he directly holds 7,228 Ordinary Shares of LivaNova.
LivaNova PLC files a Form 144 notice reporting proposed sales of Common Stock. The notice lists a broker address at Merrill Lynch, NASDAQ as the market, and a trade date of 05/26/2026. The excerpt also shows prior restricted stock unit vesting events on 06/15/2019 (20 shares), 06/18/2020 (1,435 shares), and 06/29/2021 (345 shares).
The filing includes numeric entries 136,350.00 and 54,933,538 in the securities section; the excerpt does not attach explicit labels for those figures beyond the table context.
LivaNova PLC reported stronger results for the quarter ended March 31, 2026, with net revenue of $362.3 million, up 14.3% from the prior-year period. The company generated net income of $22.3 million, compared with a net loss of $327.3 million a year earlier, when it recorded a large SNIA environmental liability charge.
Cardiopulmonary revenue rose 18.3% to $208.7 million, helped by Essenz Perfusion System sales and consumables demand, while Neuromodulation revenue grew 9.3% to $151.8 million on higher implants and pricing. Operating income declined modestly to $41.5 million as research and development spending increased, including expenses tied to ImThera contingent consideration and sleep apnea device development.
The company ended the quarter with cash and cash equivalents of $539.7 million and total debt of $287.8 million after early repaying $95.9 million under its term facilities. LivaNova recorded a current SNIA environmental liability of $389.5 million and a Saluggia site environmental provision of $41.0 million, and noted it believes it has sufficient resources to satisfy the SNIA obligation.
LivaNova PLC reported strong first-quarter 2026 results and raised its full-year outlook. Q1 net revenue was $362.3 million, up 14.3% year over year (11.1% on a constant-currency basis), led by Cardiopulmonary and Neuromodulation growth across all regions.
U.S. GAAP diluted EPS was $0.40 versus a prior-year diluted loss per share of $6.01, which had included a large SNIA environmental charge. Adjusted diluted EPS rose to $0.98 from $0.88. The company generated $15.2 million of net cash from operating activities and $3.8 million of adjusted free cash flow.
LivaNova now expects 2026 revenue to grow 7.0%–8.0% on a constant-currency basis and adjusted diluted EPS of $4.20–$4.30, while maintaining adjusted free cash flow guidance of $160–$180 million. The company also received FDA premarket approval for its aura6000 system for moderate to severe obstructive sleep apnea, positioning it for entry into the OSA market.
LivaNova PLC reports an amended joint Schedule 13G/A disclosing passive shared voting and dispositive interests held by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filing lists 2,321,067 shares (shared) for Integrated Core Strategies and 2,438,671 shares (shared) for Millennium-related filers, each representing approximately 4.2% and 4.4% of the class respectively.
The filing includes a Joint Filing Agreement dated April 29, 2026 and states these positions are held through entities subject to voting control and investment discretion by Millennium affiliates.